New & Notable
Will obesity drugs save Pfizer from its post-COVID slump?
With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity pipeline.
— PharmaVoice
Structure's GLP-1 obesity pill could compete with others on the market
Phase 2 data suggests Structure Therapeutics' GLP-1 pill, aleniglipron, could be a potential competitor in the growing market for oral obesity treatments, analysts say.
Pfizer, Innovent strike $10B cancer drug deal
Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.
— BioPharma Dive
Can AI crack pharma’s drug repurposing goldmine?
With AI now capable of analyzing decades’ worth of data, FDA is pushing pharma to leverage its “enormous, uptapped value” by repurposing drugs.
— PharmaVoiceLilly dives into vaccine research with 3 biotech buyouts
— BioPharma DiveLilly’s triple-acting obesity drug hits goal in Phase 3 trial
— BioPharma DiveFDA chief Marty Makary resigns from agency, ending tumultuous tenure
— BioPharma DiveHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Deloitte warns of a "bubble effect" caused by the GLP-1 boom
GLP-1 therapies have helped boost Big Pharma's R&D returns for the third year in a row, but Deloitte warns that the industry's focus on these treatments is fueling a "bubble effect."
-
FDA moves toward real-time review of clinical trial data
Real-time clinical trials are a key step toward the FDA's "ultimate goal" of facilitating continuous trials, the federal agency says.
-
Boehringer's dual agonist obesity drug spurs up to 16.6% weight loss
Boehringer Ingelheim's dual-acting obesity shot led to weight loss comparable to Wegovy but could potentially help patients preserve more muscle mass.
-
Merck inks $1 billion AI drug development deal with Google Cloud
The multiyear pact aims to speed up drug development and boost productivity across the pharma giant's global operations.
-
OpenAI debuts AI model GPT-Rosalind to speed up drug discovery
Biopharma companies, including Moderna and Amgen, are working with OpenAI to integrate its new artificial intelligence model into their workflows to accelerate research and discovery.
-
AWS launches AI-driven tool to speed up early-stage antibody discovery
Amazon Web Services launches Amazon Bio Discovery, an AI-powered drug discovery tool to help speed up the development of antibody therapies.
Features
-
5 emerging AI/ML trends in clinical research
Emerging AI and machine learning tools are reshaping clinical research as trial sponsors continue to grapple with rising costs, lengthy timelines and low success rates.
-
5 trends defining the next wave of life sciences M&A
As the market rebounds, five key trends are shaping the next wave of mergers and acquisitions in the life sciences industry.
-
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.